Mann added that the findings confirm that the benefits of semaglutide in chronic kidney disease extend beyond traditional clinical end points to subjective outcomes that matter directly to patients. The findings come amid growing recognition of CKDs global burden, which affects more than 850 million people worldwide, and may inform discussions about patient-centered treatment goals.
Among the innovative options we offer is Ozempic ( semaglutide ), a medication that has shown substantial promise in supporting long-term weight loss
References Luconi M, Cantini G, Ceriello A, Mannucci E
Medical providers warn that over time, the increased strain on bones, tendons, and joints may cause broader musculoskeletal issues
Furthermore, Ozempics flexible dosing options allow customization based on patient response, enhancing treatment satisfaction and outcomes